⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BEAM News
Beam Therapeutics Inc. Common Stock
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
accessnewswire.com
BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
accessnewswire.com
BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
accessnewswire.com
BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
prnewswire.com
BEAM
CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight
globenewswire.com
NVS
ALLO
LEGN
CBIO
MBIO
CRSP
INCY
IMPP
SANA
VOR
CARG
AUTL
ARCL
LYEL
PRE
BEAM
CART
TAK
AZN
MRK
BMY
GEN
DGX
GMAB
ABBV
RLGT
CRGO
JNJ
GILD
JAZZ
SYBX
CASI
ATRA
SHEN
BIIB
VREX
Rare Disease Genome Editing Market to Hit USD 12.60 Billion by 2035, Growing at a CAGR of 11.28% - SNS Insider
globenewswire.com
NTLA
BEAM
CRSP
VRTX
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
globenewswire.com
BEAM
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
globenewswire.com
BEAM
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
globenewswire.com
BEAM
As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene Therapy
globenewswire.com
AGIO
BEAM